Previous 10 | Next 10 |
Neurotrope’s ([[NTRP]] +3.0%) Board of Directors approved the conditional distribution in connection with the previously announced spin-off of its wholly-owned subsidiary, Neurotrope Bioscience, Inc.Shareholders and certain warrant holders of record of Neurotrope on November 30, 2020, ...
Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates Spin-Off Distribution is Conditional Upon the Closing of Neurotrope's Proposed Merger with Metuchen Pharmaceuticals PR Newswire NEW YORK, Nov. 20, 2020 NEW ...
Neurotrope ([[NTRP]]) has dosed the first patient in Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease ((AD)). The study will be conducted in collaboration with the National Institutes of Health ((NIH)) under $2.7M grant to Neurotrope.The 100-subject study, will eval...
Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease - Study Being Conducted in Collaboration with NIH Under a $2.7 Million Grant - PR Newswire NEW YORK, Oct. 6, 2020 NEW YORK , Oct. 6, 2020 /PRNewswir...
Mesoblast (MESO) -37% after FDA rejects cell therapy application for treatment-resistant graft-vs-host disease.Benitec Biopharma (BNTC) -26%.Greenpro Capital (GRNQ) -18%.Tuniu (TOUR) -14%.Hall of Fame Resort & Entertainment (HOFV) -13%.Iterum Therapeutics (ITRM) -12%.Oxbridge Re...
Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon...
Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen Neurotrope Shareholders, Currently Representing 34 Percent of Shares Outstanding, Sign Agreement in Support of Merger Petros to Grow Stendra® and Explore Non-Prescription / ...
NEW YORK , July 30, 2020 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced that its wholly-owned subsidiary, Neurotrope Bioscience, Inc. ("NBI"), has entered into a services agreement with Worldwide Clinical Trials ("WCT") to support site...
Neurotrope (NASDAQ: NTRP ) inks an agreement with BryoLogyx to supply synthetic Bryostatin-1, manufactured by Albany Molecular Research, for its clinical trials in Alzheimer's disease and other neurodegenerative disorders and commercial use, if approved. More news on: Neurotrope, Inc., H...
DPW Holdings DPW +198% on $3.2M of defense orders . More news on: Plus Therapeutics, Inc., Genius Brands International, Inc., Fang Holdings Limited, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
SUNRISE, FL / ACCESSWIRE / July 19, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, received a notice (the "Notice") from the listing qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on July 17, 2024 stating the...
Dynamic Content-to-Commerce FAST Channel Reinvents Monetization Models SUNRISE, FL / ACCESSWIRE / July 18, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, today announced that it has partnered with OTT ("over-the-top") services...
Allows Consumers to Pay for Accommodations Through Interest-free Installments with Convenient and Flexible Payment Options when Booking Travel Seamless Integration Enables Marketing Opportunities in Social Media Travel Package Campaigns and Direct-to-Consumer Marketing Channels to Drive Sale...